Hematopoietic stem cells transplantation can normalize thyroid function in a cystinosis mouse model

Endocrinology

Volumn 157, Issue 4, 2016, Pages 1363-1371

  Gaide Chevronnay, H P ^a   Janssens, V ^a   Van Der Smissen, P ^a   Rocca, C J ^b   Liao, X H ^c   Refetoff, S ^c   Pierreux, C E ^a   Cherqui, S ^b   Courtoy, P J ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOTUBE; THYROGLOBULIN; AMINO ACID TRANSPORTER; CYSTINE; CYSTINOSIN PROTEIN, MOUSE; PHOTOPROTEIN; THYROTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYSTINOSIS; ENDOPLASMIC RETICULUM STRESS; ENGRAFTMENT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYPOTHYROIDISM; IMMUNOGLOBULIN PRODUCTION; KIDNEY TUBULE CELL; LYSOSOME; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEADY STATE; THYROID FUNCTION; TISSUE REPAIR; ALLOTRANSPLANTATION; ANIMAL; C57BL MOUSE; CONFOCAL MICROSCOPY; DISEASE MODEL; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; THYROID GLAND; TRANSGENIC MOUSE;

AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; CELL DIFFERENTIATION; CYSTINE; CYSTINOSIS; DISEASE MODELS, ANIMAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LUMINESCENT PROTEINS; LYSOSOMES; MACROPHAGES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; THYROID GLAND; THYROTROPIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84964501721     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1762     Document Type: Article

References (29)

1. Gahl WA, Thoene J, Schneider JA. Cystinosis: a disorder of lysosomal membrane transport. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Basis of Inherited Disease. Vol 3, 8th ed. McGraw-Hill Companies, Inc, New York; 2001:5085-5108. Online update; 2013.
2. Andrzejewska Z, Nevo N, Thomas L, et al. Cystinosin is a component of the v-ATPase-Ragulator-Rag complex controlling mTORC1. J Am Soc Nephrol. In press.
3. Chan AM, Lynch MJ, Bailey JD, Ezrin C, Fraser D. Hypothyroidism in cystinosis. A clinical, endocrinologic and histologic study involving sixteen patients with cystinosis. Am J Med. 1970;48(6):678-692.
4. Lucky AW, Howley PM, Megyesi K, Spielberg SP, Schulman JD. Endocrine studies in cystinosis: compensated primary hypothyroidism. J Pediatr. 1977;91(2):204-210.
5. Nevo N, Chol M, Bailleux A, et al. Renal phenotype of the cystinosis mouse model is dependent upon genetic background. Nephrol Dialysis Transplant. 2010;25(4):1059-1066.
6. Raggi C, Luciani A, Nevo N, Antignac C, Terryn S, Devuyst O. Dedifferentiation and aberrations of the endolysosomal compartment characterize the early stage of nephropathic cystinosis. Hum Mol Genet. 2014;23(9):2266-2278.
7. Gaide Chevronnay HP, Janssens V, et al. Time course of pathogenic and adaptation mechanisms in cystinotic mouse kidneys. J Am Soc Nephrol. 2014;25(6):1256-1269.
8. Gaide Chevronnay HP, Janssens V, Van Der Smissen P, et al. A mouse model suggests two mechanisms for thyroid alterations in infantile cystinosis: decreased thyroglobulin synthesis due to endoplasmic reticulum stress/unfolded protein response and impaired lysosomal processing. Endocrinology. 2015;156(6):2349-2364.
9. Ivanova EA, De Leo MG, Van Den Heuvel L, et al. Endo-lysosomal dysfunction in human proximal tubular epithelial cells deficient for lysosomal cystine transporter cystinosin. PloS One. 2015;10(3): e0120998.
10. Jezegou A, Llinares E, Anne C, et al. Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. Proc Natl Acad Sci USA. 2012; 109(50):E3434-E3443.
11. Brodin-Sartorius A, Tete MJ, Niaudet P, et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int. 2012;81(2):179-189.
12. Emma F, Nesterova G, Langman C, et al. Nephropathic cystinosis: an international consensus document. Nephrol Dialysis Transplant. 2014;29(suppl 4):iv87-iv94.
13. Syres K, Harrison F, Tadlock M, et al. Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood. 2009;114(12):2542-2552.
14. Yeagy BA, Harrison F, Gubler MC, Koziol JA, Salomon DR, Cherqui S. Kidney preservation by bone marrow cell transplantation in hereditary nephropathy. Kidney Int. 2011;79(11):1198-1206.
15. Harrison F, Yeagy BA, Rocca CJ, Kohn DB, Salomon DR, Cherqui S. Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis.MolTher. 2013;21(2):433-444.
16. Rocca CJ, Kreymerman A, Ur SN, et al. Treatment of inherited eye defects by systemic hematopoietic stem cell transplantation. Invest Ophthalmol Vis Sci. 2015;56(12):7214-7223.
17. Naphade S, Sharma J, Gaide Chevronnay HP, et al. Brief reports: lysosomal cross-correction by hematopoietic stem cell-derived macrophages via tunneling nanotubes. Stem Cells. 2015;33(1):301-309.
18. Pohlenz J, Maqueem A, Cua K, Weiss RE, Van Sande J, Refetoff S. Improved radioimmunoassay for measurement of mouse thyrotropin in serum: strain differences in thyrotropin concentration and thyrotroph sensitivity to thyroid hormone. Thyroid. 1999;9(12): 1265-1271.
19. Lagasse E, Connors H, Al-Dhalimy M, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000; 6(11):1229-1234.
20. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14-20.
21. Gratwohl A, Baldomero H, Gratwohl M, et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a global observational study. Haematologica. 2013;98(8):1282-1290.
22. Milenkovic T, Vujic D, Vukovic R, et al. Subclinical hypothyroidism in children and adolescents after hematopoietic stem cells transplantation without irradiation. Vojnosanit Pregl. 2014;71(12):1123-1127.
23. Vantyghem MC, Cornillon J, Decanter C, et al. Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation. Orphanet J Rare Dis. 2014;9:162.
24. Choi EW, Shin IS, Lee HW, et al. Transplantation of CTLA4Ig gene-transduced adipose tissue-derived mesenchymal stem cells reduces inflammatory immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis. J Gene Med. 2011; 13(1):3-16.
25. Choi EW, Shin IS, Park SY, et al. Characteristics of mouse adipose tissue-derived stem cells and therapeutic comparisons between syngeneic and allogeneic adipose tissue-derived stem cell transplantation in experimental autoimmune thyroiditis. Cell Transplant. 2014;23(7):873-887.
26. Molne J, Jansson S, Ericson LE, Nilsson M. Adherence of RFD-1 positive dendritic cells to the basal surface of thyroid follicular cells in Graves' disease. Autoimmunity. 1994;17(1):59-71.
27. Wilders-Truschnig MM, Kabel PJ, Drexhage HA, et al. Intrathyroidal dendritic cells, epitheloid cells, and giant cells in iodine deficient goiter. Am J Pathol. 1989;135(1):219-225.
28. Irvine WJ, Muir AR. An electron microscopic study of Hashimoto thyroiditis. Q J Exp Physiol Cogn Med Sci. 1963;48:13-26.
29. Tedelind S, Ericson LE, Karlsson JO, Nilsson M. Interferon-gamma down-regulates claudin-1 and impairs the epithelial barrier function in primary cultured human thyrocytes. Eur J Endocrinol. 2003; 149(3):215-221.